Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Definium Therapeutics, Inc. filings document the regulatory record of a British Columbia clinical-stage biopharmaceutical company traded on Nasdaq as DFTX. Current reports on Form 8-K disclose financial results, corporate highlights, investor-presentation materials, and clinical and commercial updates for DT120 ODT in psychiatric indications.
Definitive proxy materials cover annual general and special meeting matters, including director elections, auditor appointment, compensation governance, and shareholder voting procedures. Other filings record board composition changes, non-employee director compensation, stock option awards, indemnity arrangements, and the company’s corporate identity following its former name, Mind Medicine (MindMed) Inc.
Definium Therapeutics, Inc. is offering $500,000,000 of common shares and pre-funded warrants pursuant to a preliminary prospectus supplement dated June 22, 2026 (subject to completion). The shares trade on Nasdaq under DFTX; the last reported sale price on June 18, 2026 was $24.48 per share.
The prospectus supplement relates to a primary shelf offering of common shares and pre-funded warrants, and discloses pro forma share counts including 104,044,508 common shares outstanding as of March 31, 2026. The offering includes a 30-day underwriter option to purchase up to an additional $75,000,000 of common shares. The supplement also summarizes recent clinical developments: the Phase 3 Emerge study in MDD met its primary and key secondary endpoints (MADRS LS mean change at Week 6: -13.3 for DT120 100 µg vs -5.2 for placebo; placebo-adjusted difference -8.1, p<0.0001).
Wiley Matthew T. reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Commercial Officer Matthew T. Wiley received an award of 62,500 common shares at no purchase price as part of his equity compensation. After this grant, he directly holds 177,500 common shares.
According to the footnote, these shares represent the first tranche of performance share units granted effective March 17, 2025. They remain subject to vesting based on his continued employment through March 17, 2028 and achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.
Barrow Robert reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Executive Officer Robert Barrow received a grant of 375,000 common shares as a stock award, with no cash paid per share. Following this award, he directly holds 1,127,454 common shares.
The shares represent the first tranche of performance share units originally granted effective March 12, 2025. They remain subject to vesting based on his continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones.
Sullivan Mark reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics Chief Legal Officer Mark Sullivan received 62,500 common shares as a performance-based equity award. The shares were granted at no purchase price and increase his direct holdings to 333,579 common shares. This tranche stems from performance share units granted effective March 12, 2025 and remains subject to vesting based on continued employment through March 12, 2028 and achievement of specified clinical and regulatory milestones.
Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts reported an equity compensation grant of 62,500 common shares at a price of $0.00 per share. These shares represent the first tranche of performance share units granted effective June 2, 2025.
The units remain subject to vesting based on her continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones in the Performance Share Unit Award Agreement. Following this award, Roberts directly holds 212,500 common shares.
Definium Therapeutics, Inc. reported that Chief Medical Officer Karlin Daniel received an award of 100,000 common shares at a price of $0.00 per share, classified as a grant or award acquisition. Following this transaction, he directly holds 513,317 common shares.
According to the footnote, these common shares represent the first tranche of performance share units granted effective March 12, 2025. They remain subject to vesting based on Daniel’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.
Definium Therapeutics reported positive topline Phase 3 results from its Emerge study of DT120 ODT 100 µg in adults with major depressive disorder. The trial met its primary endpoint, showing an 8.1-point placebo-adjusted improvement in MADRS depression scores at Week 6 (p<0.0001), and maintained a 7.3-point advantage at Week 12 (p<0.0001). A key secondary endpoint, the CGI-S severity scale, also improved rapidly, with a 0.9-point placebo-adjusted benefit by Day 2 (p<0.0001). DT120 ODT was generally well tolerated, with 99% of treatment-emergent adverse events mild to moderate, no serious adverse events, and no suicidality signal, and all participants cleared the monitored dosing session by 8 hours. Response and remission rates at Week 6 favored DT120 ODT, and interim extension data suggest additional open-label doses can deepen and sustain benefit through Week 28.
Definium Therapeutics director Crystal Roger received new equity awards as part of her compensation. She was granted 4,666 restricted stock units, each representing the right to receive one common share, and now holds 24,289 common shares after this award.
Roger was also granted a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with any remaining unvested portion vesting immediately before the company’s next annual meeting if it occurs within a year, subject to her continued service.
Definium Therapeutics director David W. Gryska received equity awards as part of his compensation. He was granted 4,666 restricted stock units, each representing one common share, and now holds 19,900 common shares directly after this grant. The filing also reports a grant of stock options for 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036.
The restricted stock units and options each vest as to 1/12 of the underlying shares on every monthly anniversary of the grant date. If the company’s first annual meeting after the grant occurs before the first anniversary, any remaining unvested RSUs and options will vest immediately before that meeting, subject to his continued service.
Definium Therapeutics director Carol A. Vallone received equity-based compensation consisting of restricted stock units and stock options. She was granted 4,666 RSUs, each representing one common share at no purchase price, bringing her direct holdings to 21,210 common shares.
Vallone also received a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest in 12 equal monthly installments from the grant date, with any remaining unvested portion vesting earlier immediately before the issuer’s next annual meeting if it occurs within the first year, subject to her continued service.